Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/13/2005WO2005037196A3 Substituted 2-arylmethylene-n-aryl-n'-aryl-malonamides and analogs as activators of caspases and inducers of apoptosis
10/13/2005WO2005033288A3 Hedgehog pathway antagonists
10/13/2005WO2005026741B1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
10/13/2005WO2005025552A3 Protein binding compounds
10/13/2005WO2005025515A3 Proteasome pathway inhibitors and related methods
10/13/2005WO2005023183A3 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
10/13/2005WO2005003150A3 Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
10/13/2005WO2005001055A3 Stabilized immunomodulatory oligonucleotides
10/13/2005WO2004105860A3 Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
10/13/2005WO2004096141A3 Method for promoting uninterrupted sleep by administration of trospium chloride
10/13/2005WO2004096118A3 Composition for improving cognition and memory
10/13/2005WO2004093876A3 Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
10/13/2005WO2004085462A3 Method and composition for decreasing ghrelin levels
10/13/2005WO2004084814A3 High viscosity xanthan polymer preparations
10/13/2005WO2004078113A3 Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
10/13/2005WO2004072253A3 Human excitatory amino acid transporter-2 gene promoter and uses thereof
10/13/2005WO2004071447A9 Substituted azole derivatives as therapeutic agents
10/13/2005WO2004064717A3 Cop 1 for treatment of inflammatory bowel diseases
10/13/2005WO2004062617A3 Composition and method for treatment of bacterial vaginal infections
10/13/2005WO2004062578A3 Methods for reducing mortality associated with acute myocardial infarction
10/13/2005WO2003065995A3 Method for treating diseases associated with abnormal kinase activity
10/13/2005WO2003031643A3 Methods for regulating co-stimulatory molecule expression with reactive oxygen
10/13/2005US20050228626 System and method for health analysis
10/13/2005US20050228384 Spinous process implant with tethers
10/13/2005US20050228383 Lateral insertion method for spinous process spacer with deployable member
10/13/2005US20050228336 Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
10/13/2005US20050228239 Method for analyzing the biological age of a subject
10/13/2005US20050228237 Method for analyzing the biological age of a subject
10/13/2005US20050228184 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
10/13/2005US20050228182 e.g., N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; used to hydrate mucosal surfaces; are absorbed less rapidly, prolonged pharmacodynamic half-life; chronic bronchitis, cystic fibrosis, sinusitis, dry eye, mucus clearance
10/13/2005US20050228180 Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
10/13/2005US20050228179 Thionation of a carbonyl compound comprising a nitrile group, the presence of a decoy agent comprising a nitrile group
10/13/2005US20050228178 Process for the synthesis of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one compounds. and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
10/13/2005US20050228177 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228055 Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof
10/13/2005US20050228054 Methods for treating eye disorders
10/13/2005US20050228053 Atamestane and toremifene dosage forms and kits for use treating breast cancer
10/13/2005US20050228052 Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
10/13/2005US20050228051 Immunoregulatory compounds and derivatives and methods of treating diseases therewith
10/13/2005US20050228050 Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same
10/13/2005US20050228049 Administering gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds; treatment of overactive bladder without loss of urine
10/13/2005US20050228048 Stable eye drops containing latanoprost as the active ingredient
10/13/2005US20050228045 Novel compounds for treatment of cardiac arrhythmia and methods of use
10/13/2005US20050228044 benzodihydrofurans; high activity at PPAR alpha receptor; no activity at PPAR gamma and PPAR delta receptors; atherosclerosis, obesity, and vascular restenosis; 5-{3-[2-Chloro-4-(2,2,2-trifluoro-ethoxy)-phenoxy]-propoxy}-2-methyl-2,3-dihydro-benzofuran-2-carboxylic acid; no 1,3-thiazolidinedione moiety
10/13/2005US20050228043 Preparation of trans-fused 3,3a,8,12b-tetrahydro-2H-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives
10/13/2005US20050228042 Statin-like compounds
10/13/2005US20050228041 Protective and therapeutic uses for tocotrienols
10/13/2005US20050228039 Luminacin analogs and uses thereof
10/13/2005US20050228038 11-Beta hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity/anti-diabetes compounds and 17-beta hydrosteroid dehydrogenase type I inhibitors as useful agents for the treatment of cancers, especially breast cancer
10/13/2005US20050228037 C10 cyclopentyl ester substituted taxanes
10/13/2005US20050228036 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
10/13/2005US20050228035 2-Pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
10/13/2005US20050228034 treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease; for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated appetite related obesity related or metabolism related syndrome, disorder or disease
10/13/2005US20050228033 Voltage-gated sodium channel (VGSC) and prostate voltage sodium channel (PVSC) inhibitors for treating diseases characterized by overabundant or hyperactive VGSC/PVSC's; phenytoin derivatives; use as sodium channel blockers, anti-cancer agents; can be used to limit or prevent PSA growth and metastasis
10/13/2005US20050228032 Antimicrobial compositions
10/13/2005US20050228031 Tyrosine kinase inhibitors
10/13/2005US20050228030 Method of using sustained release aminopyridine compositions
10/13/2005US20050228029 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis
10/13/2005US20050228026 (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2 -pyridinyl)methyl)sulfinyl)-1H-benzimidazole, (R(+)-lansoprazole); antiulcer agent
10/13/2005US20050228025 Substituted oxindole derivatives as tyrosine kinase inhibitors
10/13/2005US20050228024 Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder
10/13/2005US20050228023 Agonist and antagonist ligands of the nociceptin receptor
10/13/2005US20050228022 blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants
10/13/2005US20050228020 Beta secretase inhibitors
10/13/2005US20050228019 Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors
10/13/2005US20050228018 Chemical compounds
10/13/2005US20050228017 Novel anticancer compounds
10/13/2005US20050228016 Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
10/13/2005US20050228014 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
10/13/2005US20050228013 e.g. 4-[3-(Furo[3,2-c]pyridin-2-yl-carbonyl)-thioureido]-benzoic acid butyl ester; viricide; hepatitis C (HCV) infections, cirrhosis, end-stage liver disease, and liver cancer; side effects reducer
10/13/2005US20050228012 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
10/13/2005US20050228011 use of carboxy-functional benzofurans or benzothiophenes to treat tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, rheumatoid arthritis, and sickle cell anemia; greater bioavailability or fewer side-effects
10/13/2005US20050228010 Antidepressant azahetorocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
10/13/2005US20050228008 Process for obtaining the polymorphic form I of finasteride
10/13/2005US20050228007 Treating cancer with tetracyclic benzamide derivatives; synthesis
10/13/2005US20050228005 Protein kinase inhibitors and uses thereof
10/13/2005US20050228004 administering drugs such as 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-amine, for therapy of viral diseases caused by DNA viruses
10/13/2005US20050228003 Mitotic kinesin inhibitors
10/13/2005US20050228002 Anti proliferavtive agents; small molecule inhibitors of KSP(kinesin-related proteins); N-(3-aminopropyl)-N-[1-(3-benzyl-4-oxo-6,7,8 ,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-2-yl)propyl]-4-bromobenzamide
10/13/2005US20050228001 Methods and compositions for treating platelet-related disorders
10/13/2005US20050228000 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent
10/13/2005US20050227999 Diarylamine derivatives as calcium channel blockers
10/13/2005US20050227998 Compositions and methods of decreasing nicotine withdrawal
10/13/2005US20050227997 Selective inhibition of aggrecanase in osteoarthritis treatment
10/13/2005US20050227996 Use of creatine or creatine compounds for skin preservation
10/13/2005US20050227995 Phenyl sulfoxides and phenyl sulfones
10/13/2005US20050227992 Protein kinase inhibitors
10/13/2005US20050227991 Containing a piperazine ring, e.g., N'-(4-{4-[5-(1,2-dithiolan-3-yl)pentanoyl]-1-piperazinyl)phenyl)-2-thiophenecarboximidamide and intermediates for preparing them; useful for inhibiting NO synthase and regenerating antioxidants
10/13/2005US20050227989 Polycyclic thiazoles as potassium ion channel modulators
10/13/2005US20050227988 compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety
10/13/2005US20050227987 11beta-hydroxysteroid dehydrogenase inhibitors
10/13/2005US20050227986 Vanilloid receptor ligands and their use in treatments
10/13/2005US20050227985 Folate mimetics and folate-receptor binding conjugates thereof
10/13/2005US20050227984 Drugs for improving the prognosis of brain injury and a method of screening the same
10/13/2005US20050227983 Triazine compounds and their analogs, compositions, and methods
10/13/2005US20050227982 Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin
10/13/2005US20050227981 Aralkyl and aralkylidene heterocyclic lactam and imides
10/13/2005US20050227980 Aralkyl and aralkylidene heterocyclic lactam and imides
10/13/2005US20050227979 E.g., 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane; these compounds modulate the activity of the histamine receptor, specifically the H3 receptor, without the inherent problems associated with the presence of an imidazolyl moiety
1 ... 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 ... 7860